Clinical and Translational Oncology

, Volume 20, Issue 4, pp 542–549 | Cite as

Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls

  • R. de Cássia Viu Carrara
  • A. M. Fontes
  • K. J. Abraham
  • M. D. Orellana
  • S. K. Haddad
  • P. V. B. Palma
  • R. A. Panepucci
  • M. A. Zago
  • D. T. Covas
Research Article



The fusion gene BCR-ABL has an important role to the progression of chronic myeloid leukemia (CML) and several signaling pathways have been characterized as responsible for the terminal blastic phase (BP). However, the initial phase, the chronic phase (CP), is long lasting and there is much yet to be understood about the critical role of BCR-ABL in this phase. This study aims to evaluate transcriptional deregulation in CD34+ hematopoietic cells (CD34+ cells) from patients with untreated newly diagnosed CML compared with CD34+HC from healthy controls.


Gene expression profiling in CML-CD34 cells and CD34 cells from healthy controls were used for this purpose with emphasis on five main pathways important for enhanced proliferation/survival, enhanced self-renewal and block of myeloid differentiation.


We found 835 genes with changed expression levels (fold change ≥ ±2) in CML-CD34 cells compared with CD34 cells. These include genes belonging to PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways. Four of these pathways converge to MYC activation. We also identified five transcripts upregulated in CD34-CML patients named OSBPL9, MEK2, p90RSK, TCF4 and FZD7 that can be potential biomarkers in CD34-CML-CP.


We show several mRNAs up- or downregulated in CD34-CML during the chronic phase.


Chronic myeloid leukemia CD34+ cells BCR-ABL Gene expression Chronic phase microRNA 


Compliance with ethical standards

Conflict of interest

There are no conflicts of interest.

Human participants

All procedures performed in studies involving human participants were in accordance with the ethical standards of the FMRP-USP Hospital and with the 1964 Helsinki declaration and its later amendments.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441–53. doi: 10.1038/nrc2147.CrossRefPubMedGoogle Scholar
  2. 2.
    Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103(11):4010–22. doi: 10.1182/blood-2003-12-4111.CrossRefPubMedGoogle Scholar
  3. 3.
    Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene. 2003;22(25):3952–63. doi: 10.1038/sj.onc.1206620.CrossRefPubMedGoogle Scholar
  4. 4.
    Kronenwett R, Butterweck U, Steidl U, Kliszewski S, Neumann F, Bork S, et al. Distinct molecular phenotype of malignant CD34+ hematopoietic stem and progenitor cells in chronic myelogenous leukemia. Oncogene. 2005;24(34):5313–24. doi: 10.1038/sj.onc.1208596.CrossRefPubMedGoogle Scholar
  5. 5.
    Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M, et al. Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia. 2007;21(3):494–504. doi: 10.1038/sj.leu.2404549.CrossRefPubMedGoogle Scholar
  6. 6.
    Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141(5):887–99. doi: 10.1007/s00432-014-1845-6.CrossRefPubMedGoogle Scholar
  7. 7.
    Heller G, Topakian T, Altenberger C, Cerny-Reiterer S, Herndlhofer S, Ziegler B, et al. Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia. Leukemia. 2016;30(9):1861–8. doi: 10.1038/leu.2016.143.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12(8):445–64. doi: 10.1038/nrclinonc.2015.61.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sengupta A, Banerjee D, Chandra S, Banerji SK, Ghosh R, Roy R, et al. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia. 2007;21(5):949–55. doi: 10.1038/sj.leu.2404657.CrossRefPubMedGoogle Scholar
  10. 10.
    Yeh CH, Moles R, Nicot C. Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer. 2016;15(1):37. doi: 10.1186/s12943-016-0518-2.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Yong AS, Melo JV. The impact of gene profiling in chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009;22(2):181–90. doi: 10.1016/j.beha.2009.04.002.CrossRefPubMedGoogle Scholar
  12. 12.
    Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007;109(10):4399–405. doi: 10.1182/blood-2006-09-045104.CrossRefPubMedGoogle Scholar
  13. 13.
    van Almen GC, Verhesen W, van Leeuwen RE, van de Vrie M, Eurlings C, Schellings MW, et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell. 2011;10(5):769–79. doi: 10.1111/j.1474-9726.2011.00714.x.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006;38(9):1060–5. doi: 10.1038/ng1855.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63(4):789–99.PubMedGoogle Scholar
  16. 16.
    Tognon R, Gasparotto EP, Leroy JM, Oliveira GL, Neves RP, Carrara Rde C, et al. Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases. J Clin Pathol. 2011;64(1):75–82. doi: 10.1136/jcp.2010.080895.CrossRefPubMedGoogle Scholar
  17. 17.
    Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98(9):5116–21. doi: 10.1073/pnas.091062498.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Skoda J, Hermanova M, Loja T, Nemec P, Neradil J, Karasek P, et al. Co-expression of cancer stem cell markers corresponds to a pro-tumorigenic expression profile in pancreatic adenocarcinoma. Plos one. 2016;11(7):e0159255. doi: 10.1371/journal.pone.0159255.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Cheng J, Liu C, Liu L, Chen X, Shan J, Shen J, et al. MEK1 signaling promotes self-renewal and tumorigenicity of liver cancer stem cells via maintaining SIRT1 protein stabilization. Oncotarget. 2016;7(15):20597–611. doi: 10.18632/oncotarget.7972.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Gargini R, Cerliani JP, Escoll M, Anton IM, Wandosell F. Cancer stem cell-like phenotype and survival are coordinately regulated by Akt/FoxO/Bim pathway. Stem Cells. 2015;33(3):646–60. doi: 10.1002/stem.1904.CrossRefPubMedGoogle Scholar
  22. 22.
    Hill R, Wu H. PTEN, stem cells, and cancer stem cells. J Biol Chem. 2009;284(18):11755–9. doi: 10.1074/jbc.R800071200.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, et al. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology. 2011;140(1):297–309. doi: 10.1053/j.gastro.2010.10.005.CrossRefPubMedGoogle Scholar
  24. 24.
    Sette G, Fecchi K, Salvati V, Lotti F, Pilozzi E, Duranti E, et al. Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. J Exp Clin Cancer Res. 2013;32:91. doi: 10.1186/1756-9966-32-91.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ciuffreda L, Falcone I, Incani UC, Del Curatolo A, Conciatori F, Matteoni S, et al. PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Adv Biol Regul. 2014;56:66–80. doi: 10.1016/j.jbior.2014.07.002.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhao Y, Zhang W, Guo Z, Ma F, Wu Y, Bai Y, et al. Inhibition of the transcription factor sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts. Oncol Rep. 2013;30(4):1782–92. doi: 10.3892/or.2013.2627.CrossRefPubMedGoogle Scholar
  27. 27.
    Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011;11:71. doi: 10.1186/1471-230X-11-71.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22–35. doi: 10.1016/j.cell.2012.03.003.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Fallah P, Amirizadeh N, Poopak B, Toogeh G, Arefian E, Kohram F, et al. Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Int J Lab Hematol. 2015;37(4):560–8. doi: 10.1111/ijlh.12351.CrossRefPubMedGoogle Scholar
  30. 30.
    Chang CC, Hsu WH, Wang CC, Chou CH, Kuo MY, Lin BR, et al. Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. Cancer Res. 2013;73(13):4147–57. doi: 10.1158/0008-5472.CAN-12-4085.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Authors and Affiliations

  1. 1.Center for Cell-Based Therapy of the Regional Blood Center of Ribeirão PretoRibeirao PretoBrazil
  2. 2.UNAERPRibeirao PretoBrazil
  3. 3.Department of Genetics, Medical School of Ribeirão PretoUniversity of São PauloRibeirao PretoBrazil
  4. 4.Department of Puericulture and Pediatrics, Medical School of Ribeirão PretoUniversity of São PauloRibeirao PretoBrazil
  5. 5.Department of Clinical Medicine, Medical School of Ribeirão PretoUniversity of São PauloRibeirao PretoBrazil

Personalised recommendations